The Impact of Pathogen Inactivation Technologies on Platelet Quality and Clot Formation.
- 1Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
- 2Department of Blood Component Production, Warsaw Regional Blood Transfusion Center, Warsaw, Poland.
Abstract
Introduction
Shrinking donor pools and increasing clinical demand increase the attractiveness of 7-day platelet shelf-life. This can be achieved with pathogen inactivation to mitigate bacterial risk. Studies directly comparing clot formation performance in 7-day platelets prepared with different pathogen inactivation technologies (PITs) have not been conducted to date. To address this gap, we compared in vitro metabolic, functional, and clot formation parameters up to 7 days in platelets prepared with the two CE-marked PITs available on the market during the time the study was conducted.Methods
Three identical whole-blood-derived platelet units in PAS-E/plasma were prepared using a pool-and-split approach. One split unit was treated with amotosalen/UVA (AS/UVA); the second with riboflavin/UVA-B (RB/UVA-B); the third was an untreated control. In vitro parameters and clot formation (ROTEM INTEM and EXTEM) were assessed on storage days 2, 5, and 7.Results
AS/UVA platelets were not significantly different from controls in most parameters. Platelets treated with RB/UVA-B showed increasing storage lesion over time. Clot formation was significantly impacted by the RB/UVA-B process, with reduced clot strength and prolonged clot formation in EXTEM and INTEM assays. Clot formation remained unaffected in the INTEM analysis and showed only minor alterations in the EXTEM analysis in AS/UVA platelets.Conclusion
Platelets in PAS-E treated with different PITs have different in vitro quality and efficacy profiles. 7-Day RB/UVA-B-treated platelet concentrates (PCs) did not retain in vitro quality parameters and cannot be recommended for transfusion, whereas/UVA PCs had acceptable in vitro quality and efficacy for transfusion at both 5 and 7 days of storage.
Related
- Dysregulated Platelet GPIb alpha - VWF Signalling in Abdominal Aortic Aneurysm formation and Progression
- Application of spectroscopic and multispectral imaging technologies on the assessment of ready-to-eat pineapple quality: A performance evaluation study of machine learning models generated from two commercial data analytics tools
- Association between quality of life and pregnancy outcomes among infertility patients undergoing assisted reproduction technologies: a prospective cohort study
- The Role of Zinc and Junctional Adhesion Molecule A Protein in Platelet Plug Formation.
- Current Approaches to the Storage, Processing, and Quality Assessment of RBC and Platelet Components: A Narrative Review
BibTeX
@article{lachert2026impact,
title = {{The Impact of Pathogen Inactivation Technologies on Platelet Quality and Clot Formation.}},
author = {Elżbieta Lachert and Joanna Lasocka and Paulina Goczyńska and Beata Baran and Agnieszka Krzywdzińska and Zofia Przybylska and Dariusz Piotrowski and Jolanta Antoniewicz-Papis},
journal = {Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie},
year = {2026},
month = aug,
doi = {10.1159/tmh/aevag003},
url = {https://europepmc.org/article/MED/42924099},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Impact of Pathogen Inactivation Technologies on Platelet Quality and Clot Formation.
AU - Elżbieta Lachert
AU - Joanna Lasocka
AU - Paulina Goczyńska
AU - Beata Baran
AU - Agnieszka Krzywdzińska
AU - Zofia Przybylska
AU - Dariusz Piotrowski
AU - Jolanta Antoniewicz-Papis
PY - 2026
DA - 2026/08/26
JO - Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
DO - 10.1159/tmh/aevag003
UR - https://europepmc.org/article/MED/42924099
AB - Introduction Shrinking donor pools and increasing clinical demand increase the attractiveness of 7-day platelet shelf-life. This can be achieved with pathogen inactivation to mitigate bacterial risk. Studies directly comparing clot formation performance in 7-day platelets prepared with different pathogen inactivation technologies (PITs) have not been conducted to date. To address this gap, we compared in vitro metabolic, functional, and clot formation parameters up to 7 days in platelets prepared with the two CE-marked PITs available on the market during the time the study was conducted.Methods Three identical whole-blood-derived platelet units in PAS-E/plasma were prepared using a pool-and-split approach. One split unit was treated with amotosalen/UVA (AS/UVA); the second with riboflavin/UVA-B (RB/UVA-B); the third was an untreated control. In vitro parameters and clot formation (ROTEM INTEM and EXTEM) were assessed on storage days 2, 5, and 7.Results AS/UVA platelets were not significantly different from controls in most parameters. Platelets treated with RB/UVA-B showed increasing storage lesion over time. Clot formation was significantly impacted by the RB/UVA-B process, with reduced clot strength and prolonged clot formation in EXTEM and INTEM assays. Clot formation remained unaffected in the INTEM analysis and showed only minor alterations in the EXTEM analysis in AS/UVA platelets.Conclusion Platelets in PAS-E treated with different PITs have different in vitro quality and efficacy profiles. 7-Day RB/UVA-B-treated platelet concentrates (PCs) did not retain in vitro quality parameters and cannot be recommended for transfusion, whereas/UVA PCs had acceptable in vitro quality and efficacy for transfusion at both 5 and 7 days of storage.
SN - 1660-3796
SN - 1660-3818
ER -